Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
1.080
-0.100 (-8.47%)
At close: Oct 29, 2024, 4:00 PM
1.090
+0.010 (0.93%)
After-hours: Oct 29, 2024, 7:55 PM EDT
Calidi Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 |
Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Revenue | - | - | 0.05 | 0.45 | - |
Revenue Growth (YoY) | - | - | -89.98% | - | - |
Cost of Revenue | - | - | 0.01 | 0.09 | - |
Gross Profit | - | - | 0.03 | 0.36 | - |
Selling, General & Admin | 17.45 | 15.98 | 15.9 | 6.16 | 3.59 |
Research & Development | 12.12 | 13.01 | 7.26 | 3.8 | 3.18 |
Operating Expenses | 29.57 | 28.99 | 23.16 | 9.96 | 6.77 |
Operating Income | -29.57 | -28.99 | -23.13 | -9.61 | -6.77 |
Interest Expense | -1.07 | -1.07 | -0.16 | -0.61 | -0.16 |
Other Non Operating Income (Expenses) | 7.88 | 1.33 | -2.13 | 0.24 | -1.05 |
EBT Excluding Unusual Items | -22.75 | -28.73 | -25.42 | -9.98 | -7.99 |
Other Unusual Items | -0.47 | -0.47 | - | -0.06 | 0.06 |
Pretax Income | -23.23 | -29.2 | -25.42 | -10.92 | -7.93 |
Income Tax Expense | 0.02 | 0.02 | 0.01 | 0.01 | 0 |
Net Income | -23.25 | -29.22 | -25.43 | -10.93 | -7.94 |
Net Income to Common | -24.92 | -29.22 | -25.43 | -10.93 | -7.94 |
Shares Outstanding (Basic) | 3 | 2 | 1 | 2 | 2 |
Shares Outstanding (Diluted) | 3 | 2 | 1 | 2 | 2 |
Shares Change (YoY) | 1173.82% | 98.55% | -56.93% | 15.26% | - |
EPS (Basic) | -7.17 | -17.30 | -29.90 | -5.54 | -4.63 |
EPS (Diluted) | -7.17 | -17.30 | -29.90 | -5.54 | -4.63 |
Free Cash Flow | -28.18 | -27.57 | -13.64 | -7.98 | -5.18 |
Free Cash Flow Per Share | -8.11 | -16.32 | -16.04 | -4.04 | -3.02 |
Gross Margin | - | - | 68.89% | 79.06% | - |
Operating Margin | - | - | -51395.56% | -2139.42% | - |
Profit Margin | - | - | -56504.44% | -2434.97% | - |
Free Cash Flow Margin | - | - | -30315.56% | -1777.28% | - |
EBITDA | -29.18 | -28.6 | -22.87 | -9.45 | -6.67 |
D&A For EBITDA | 0.39 | 0.39 | 0.26 | 0.16 | 0.11 |
EBIT | -29.57 | -28.99 | -23.13 | -9.61 | -6.77 |
Revenue as Reported | - | - | 0.05 | - | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.